The impact of regional disparities on the availability of meningococcal vaccines in the US.
Access barriers
Inequality
Invasive meningococcal disease
Meningococcal vaccination
Shared clinical decision making
Social equity
Vaccine access
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
received:
22
12
2023
accepted:
07
06
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
3
7
2024
Statut:
epublish
Résumé
In the United States (US), three types of vaccines are available to prevent invasive meningococcal disease (IMD), a severe and potentially fatal infection: quadrivalent conjugate vaccines against serogroups A, C, W, Y (MenACWY), and monovalent vaccines against serogroup B (MenB) as well as a newly licensed pentavalent vaccine (MenABCWY) protecting against serogroup A, B, C, W, and Y. The CDC's Advisory Committee on Immunization Practices (ACIP) routinely recommends MenACWY vaccine for all 11- to 12-year-olds with a booster dose at 16 years. MenB vaccination is recommended based on shared clinical decision-making (SCDM) for 16- to 23-year-olds. Recently, the pentavalent meningococcal vaccine (MenABCWY) was recommended by the ACIP. Meningococcal vaccine uptake is suboptimal across the country, particularly among individuals with lower socioeconomic status (SES), despite these recommendations. The objective of the spatial analyses was to assess the relationship between stocking of MenACWY and MenB vaccines, area-level SES, and state-level policies. The number of MenACWY and MenB doses stocked by vaccinators was obtained from IQVIA and the CDC's Vaccine for Children (VFC) program and compiled into a county-level dataset from 2016 to 2019. SES, as measured using the CDC's Social Vulnerability Index (SVI), state-level school recommendations, and universal purchasing programs were among the main county-level covariates included to control for factors likely influencing stocking. Data were stratified by public and private market. Bayesian spatial regression models were developed to quantify the variations in rates of stocking and the relative rates of stocking of both vaccines. After accounting for county-level characteristics, lower SES counties tended to have fewer doses of MenB relative to MenACWY on both public and private markets. Lower SES counties tended to have more supply of public vs. private doses. Universal purchasing programs had a strong effect on the markets for both vaccines shifting nearly all doses to the public market. School vaccination strategy was key for improving stocking rates. Overall, the results show that MenACWY has greater stock relative to MenB across the US. This difference is exacerbated in vulnerable areas without school entry requirements for vaccination and results in inequity of vaccine availability. Beyond state-level policy and SES differences, SCDM recommendations may be a contributing factor, although this was not directly assessed by our model.
Sections du résumé
BACKGROUND
BACKGROUND
In the United States (US), three types of vaccines are available to prevent invasive meningococcal disease (IMD), a severe and potentially fatal infection: quadrivalent conjugate vaccines against serogroups A, C, W, Y (MenACWY), and monovalent vaccines against serogroup B (MenB) as well as a newly licensed pentavalent vaccine (MenABCWY) protecting against serogroup A, B, C, W, and Y. The CDC's Advisory Committee on Immunization Practices (ACIP) routinely recommends MenACWY vaccine for all 11- to 12-year-olds with a booster dose at 16 years. MenB vaccination is recommended based on shared clinical decision-making (SCDM) for 16- to 23-year-olds. Recently, the pentavalent meningococcal vaccine (MenABCWY) was recommended by the ACIP. Meningococcal vaccine uptake is suboptimal across the country, particularly among individuals with lower socioeconomic status (SES), despite these recommendations. The objective of the spatial analyses was to assess the relationship between stocking of MenACWY and MenB vaccines, area-level SES, and state-level policies.
METHODS
METHODS
The number of MenACWY and MenB doses stocked by vaccinators was obtained from IQVIA and the CDC's Vaccine for Children (VFC) program and compiled into a county-level dataset from 2016 to 2019. SES, as measured using the CDC's Social Vulnerability Index (SVI), state-level school recommendations, and universal purchasing programs were among the main county-level covariates included to control for factors likely influencing stocking. Data were stratified by public and private market. Bayesian spatial regression models were developed to quantify the variations in rates of stocking and the relative rates of stocking of both vaccines.
RESULTS
RESULTS
After accounting for county-level characteristics, lower SES counties tended to have fewer doses of MenB relative to MenACWY on both public and private markets. Lower SES counties tended to have more supply of public vs. private doses. Universal purchasing programs had a strong effect on the markets for both vaccines shifting nearly all doses to the public market. School vaccination strategy was key for improving stocking rates.
CONCLUSIONS
CONCLUSIONS
Overall, the results show that MenACWY has greater stock relative to MenB across the US. This difference is exacerbated in vulnerable areas without school entry requirements for vaccination and results in inequity of vaccine availability. Beyond state-level policy and SES differences, SCDM recommendations may be a contributing factor, although this was not directly assessed by our model.
Identifiants
pubmed: 38961431
doi: 10.1186/s12889-024-19081-w
pii: 10.1186/s12889-024-19081-w
doi:
Substances chimiques
Meningococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1771Informations de copyright
© 2024. The Author(s).
Références
Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.
doi: 10.1016/j.micpath.2019.103571
pubmed: 31163252
Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(RR–9):1–41.
doi: 10.15585/mmwr.rr6909a1
pubmed: 33417592
pmcid: 7527029
CDC. Enhanced Meningococcal Disease Surveillance Report. 2019. Accessed October 5, 2023. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2019.pdf
CDC. Enhanced Meningococcal Disease Surveillance Report. 2021. Date: June 21, 2023. Accessed: October 10, 2023. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf
Wang B, Santoreneos R, Giles I, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. https://doi.org/10.1016/j.vaccine.2019.04.020
doi: 10.1016/j.vaccine.2019.04.020
pubmed: 30987851
Voss SS, Nielsen J, Valentiner-Branth P. Risk of sequelae after invasive meningococcal disease. BMC Infect Dis. 2022;22:148. https://doi.org/10.1186/s12879-022-07129-4 . https://bmcinfectdis.biomedcentral.com/articles/
doi: 10.1186/s12879-022-07129-4
pubmed: 35148717
pmcid: 8831877
CDC. ACIP Shared Clinical Decision-Making Recommendations. Last reviewed: February 10, 2020. Accessed July 19, 2023. https://www.cdc.gov/vaccines/acip/acip-scdm-faqs.html
Scalia P, Durand M-A, Elwyn G. Shared decision-making interventions: an overview and a meta-analysis of their impact on vaccine update. J Intern Med. 2022;291(3):408–25.
doi: 10.1111/joim.13405
pubmed: 34700363
Yonts AB, et al. Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and other Pediatric vaccines. Pediatrics. 2023. https://doi.org/10.1542/peds.2023-064990
doi: 10.1542/peds.2023-064990
pubmed: 37641189
CDC. Supplementary Table 1. Vaccination coverage among adolescents aged 13–17 years – national immunization survey – teen, United States, 2022. Last updated: August 25, 2023. Accessed: October 10, 2023. https://stacks.cdc.gov/view/cdc/132006
Pingali C, Yankey D, Elam-Evans LD et al. Vaccination coverage among adolescents aged 13–17 years — national immunization survey-teen, United States, 2022. Morbidity and Mortality Weekly Report (MMWR). 2023;72(34):912–9.
Masaquel C, Schley K, Wright K, et al. The impact of social determinants of health on meningococcal vaccination awareness, delivery, and coverage in adolescents and young adults in the United States: a systematic review. Vaccines. 2023;11(2):256. https://doi.org/10.3390/vaccines11020256
doi: 10.3390/vaccines11020256
pubmed: 36851134
pmcid: 9962690
CDC. Evidence to Recommendations Framework. Last reviewed: January 23. 2023. accessed October 18, 2023. https://www.cdc.gov/vaccines/acip/recs/grade/etr.html
Rodriguez Santana I, Mason A, Gutacker N, et al. Need, demand, supply in health care: working definitions, and their implications for defining access. Health Econ Policy Law. 2023;18(1):1–13. https://doi.org/10.1017/S1744133121000293
doi: 10.1017/S1744133121000293
pubmed: 36515132
FEMA. CDC social vulnerability index. Last updated: June 23, 2022. Accessed: June 26. 2023. https://www.fema.gov/node/cdc-social-vulnerability-index
CDC. CDC/ATSDR Social Vulnerability Index (SVI). Last reviewed: July 12, 2023. Accessed: October 10, 2023. https://www.atsdr.cdc.gov/placeandhealth/svi/index.html
US Census Bureau. American Community Survey 2015–2019 5-Year Data Release (census.gov). December 10, 2020. Accessed: June 26, 2023. https://www.census.gov/newsroom/press-kits/2020/acs-5-y
Abla H, Collins RA, Dhanasekara CS et al. Using the social vulnerability index to analyze statewide health disparities in cholecystectomy. J Surg Res 2024 Apr:296:135–41. https://doi.org/10.1016/j.jss.2023.12.031
Institute of Medicine (US) Committee on Immunization Finance Policies and Practices. Calling the Shots: Immunization Finance Policies and Practices. Washington (DC): National Academies Press (US). 2000. 3, Financing Vaccine Purchase and Delivery. Accessed June 22, 2023. https://www.ncbi.nlm.nih.gov/books/NBK225576/
Pruitt SL, Tiro JA, Kepka D, Henry K. Missed Vaccination opportunities among U.S. adolescents by Area characteristics. Am J Prev Med. 2022;62(4):538–47. https://doi.org/10.1016/j.amepre.2021.10.014
doi: 10.1016/j.amepre.2021.10.014
pubmed: 35125272
pmcid: 10228151
Centers for Disease Control and Prevention (CDC). About Vaccines for Children (VCF). Last reviewed: February 18, 2016. Accessed July 27. 2023. https://www.cdc.gov/vaccines/programs/vfc/about/index.html
US Army Basic. Army shots. Accessed September 10. 2023. https://usarmybasic.com/about-the-army/army-shots/#google_vignette
Hutton DW, Rose A, Singer DC, et al. Importance of reasons for stocking adult vaccines. Am J Manag Care. 2019;25(11):e334–41. Published 2019 Nov 1.
pubmed: 31747238
pmcid: 9004468
Kempe A, Lindley MC, O’Leary ST, et al. Shared Clinical decision-making recommendations for adult immunization: what do Physicians think? J Gen Intern Med. 2021;36(8):2283–91. https://doi.org/10.1007/s11606-020-06456-z
doi: 10.1007/s11606-020-06456-z
pubmed: 33528783
pmcid: 8342675
Basta NE, Becker AB, Li O, Nederhoff D. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens. Vaccine. 2019;37(4):670–6. https://doi.org/10.1016/j.vaccine.2018.11.078
doi: 10.1016/j.vaccine.2018.11.078
pubmed: 30587431
Coulter J, Whichello C, Heidenreich S et al. From qualitative research to quantitative preference elicitation: an example in invasive meningococcal disease. Patient. 2024 Feb 23. https://doi.org/10.1007/s40271-024-00677-8
Schillie S. Revising the adolescent meningococcal vaccine schedule: term of reference and considerations. February 29, 2024. CDC, ACIP meeting. Accessed April 22, 2024. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/02-Meningitis-Schillie-508.pdf
Niccolai LM, Yakely AE, Hansen CE. Up-to-date coverage with meningococcal vaccine among adolescents age 17 years: patterns and correlates in the United States, 2017. Vaccine. 2019;37:5934–8. https://doi.org/10.1016/j.vaccine.2019.08.015
doi: 10.1016/j.vaccine.2019.08.015
pubmed: 31473004
Franco M, Mazzucca S, Padek M, Brownson RC. Going beyond the individual: how state-level characteristics relate to HPV vaccine rates in the United States. BMC Public Health. 2019;19(1):246–246. https://doi.org/10.1186/s12889-019-6566-y
doi: 10.1186/s12889-019-6566-y
pubmed: 30819149
pmcid: 6393974
Shaw J, Mader EM, Bennett BE, Vernyi-Kellogg OK, Yang YT, Morley CP. Immunization mandates, vaccination coverage, and exemption rates in the United States. Open Forum Infect Dis. 2018;5(6):ofy130. https://doi.org/10.1093/ofid/ofy130.76
doi: 10.1093/ofid/ofy130.76
pubmed: 29977973
pmcid: 6016709
Middleman AB. New adolescent vaccination recommendations and how to make them stick. Curr Opin Pediatr. August 2007;19(4):411–6. https://doi.org/10.1097/MOP.0b013e3281e72cd2
Bart SM, Eberhart M, Feemster K. Impact of a category B recommendation: Meningococcal B (MenB) vaccine uptake among adolescents in Philadelphia county. 2018. Accessed July 19, 2023. https://plan.coreapps.com/pas2018/abstract/e5177900e60498db774eaebbee6695f0
La EM, Garbinsky D, Hunter S, et al. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021;39:2660–7. https://doi.org/10.1016/j.vaccine.2021.03.071
doi: 10.1016/j.vaccine.2021.03.071
pubmed: 33849722
Marshall GS, Ghaswalla PK, Bengtson LGS, et al. Low meningococcal vaccination rates among patients with newly diagnosed complement component deficiencies in the United States. Clin Infect Dis. 2022;75(1):155–8.
doi: 10.1093/cid/ciab917
pubmed: 34718466